Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes.
Saved in:
| Title: | Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. |
|---|---|
| Authors: | Shah P; Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Forget MA; Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Biologics Development, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Frank ML; Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jiang P; Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sakellariou-Thompson D; Biologics Development, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Federico L; Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Khairullah R; Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Neutzler CA; Biologics Development, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wistuba I; Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Chow CB; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Long Y; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Fujimoto J; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Lin SY; Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Maitra A; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Negrao MV; Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Mitchell KG; Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Weissferdt A; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Vaporciyan AA; Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Cascone T; Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Roth JA; Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Zhang J; Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sepesi B; Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gibbons DL; Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Heymach JV; Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Haymaker CL; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., McGrail DJ; Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA cbernatchez@mdanderson.org AReuben@mdanderson.org djmcgrail@mdanderson.org., Reuben A; Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA cbernatchez@mdanderson.org AReuben@mdanderson.org djmcgrail@mdanderson.org., Bernatchez C; Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA cbernatchez@mdanderson.org AReuben@mdanderson.org djmcgrail@mdanderson.org.; Biologics Development, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Feb; Vol. 10 (2). |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
